TRAF6 and colorectal carcinoma: Therefore, if we select small molecule compounds that block RGS16’s binding to the TRAF6/TAB2 complex by screening the library of natural or synthetic small molecule compounds, we can develop novel potential therapies for CRC through targeting RGS16.